Publisher correction: death by inflammation: drug makers chase the master controller

Correction to: _Nature Biotechnology_ https://doi.org/10.1038/s41587-019-0023-4, published online 4 February 2019. In the version of this article initially published, a GlaxoSmithKline

compound referred to as GSK298559 was listed in Table 1 as a RIPK1 inhibitor in phase 1 trials for inflammatory bowel disease. The correct designation is GSK2983559; however, this compound

is a RIPK2 inhibitor and thus should not have been included in the table in question. The table row has been deleted. The error has been corrected in the HTML and PDF versions of the

article. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Dublin, Ireland Cormac Sheridan Authors * Cormac Sheridan View author publications You can also search for this author inPubMed Google

Scholar CORRESPONDING AUTHOR Correspondence to Cormac Sheridan. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Sheridan, C. Publisher Correction: Death

by inflammation: drug makers chase the master controller. _Nat Biotechnol_ 37, 480 (2019). https://doi.org/10.1038/s41587-019-0082-6 Download citation * Published: 06 March 2019 * Issue

Date: April 2019 * DOI: https://doi.org/10.1038/s41587-019-0082-6 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative